

February 28, 2019

BSE Limited P. J. Towers Dalal Street, Fort Mumbai – 400 001

National Stock Exchange of India Limited Exchange Plaza Bandra Kurla Complex, Bandra (E) Mumbai – 400 051

Dear Sirs,

Sub: Issuance of rated unsecured bonds by our wholly-owned subsidiary Jubilant Pharma Limited (a company incorporated under the laws of Singapore), outside India, under Regulation S of the U.S. Securities Act of 1933, as amended.

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, and further to the disclosure made to the stock exchanges on February 25, 2019, we wish to inform you that our material wholly-owned subsidiary, Jubilant Pharma Limited (a company incorporated under the laws of Singapore) ("JPL") has successfully priced its rated unsecured bonds (the "Notes") at 6.00% per annum issued at par for US\$200 million maturing in March, 2024.

S&P Global Ratings ("**S&P**") has affirmed BB-/positive rating and Fitch Ratings ("**Fitch**") has affirmed BB-/Stable rating for JPL (the issuer of the Notes). The Notes have been rated BB- by S&P and BB by Fitch.

The major portion of the net proceeds of the Notes shall be used to refinance existing indebtedness and pay associated fees and premiums over a period of time and the balance amount for working capital and general corporate purposes.

A Jubilant Bhartia Company



Jubilant Life Sciences Limited 1-A, Sector 16-A, Noida-201 301, UP, India Tel:+91 120 4361000 Fax:+91 120 4234895-96 www.jubl.com Regd Office: Bhartiagram, Gajraula Distt. Amroha - 244 223, UP, India CIN : L24116UP1978PLC004624



The above is for your information and records. The Company will provide further updates in this regard, if and when necessary.

We request you to take the same on record.

Thanking you,

Yours Faithfully, For Jubilant Life Sciences Limited

Rajiv Shah Company Secretary

This announcement is not for distribution in or into the United States. This announcement is not an offer of securities for sale in the United States. Securities may not be offered or sold in the United States unless they are registered or are exempt from registration. Any public offering of securities to be made in the United States would be made by means of a prospectus that would contain detailed information about the issuer, their management and their financial statements in compliance with all relevant laws. The issuer does not have any current intention to make any public offering of, or to register, any securities in the United States.

A Jubilant Bhartia Company



Jubilant Life Sciences Limited 1-A, Sector 16-A, Noida-201 301, UP, India Tel:+91 120 4361000 Fax:+91 120 4234895-96 www.jubl.com Regd Office: Bhartiagram, Gajraula Distt. Amroha - 244 223, UP, India CIN : L24116UP1978PLC004624